Tardive dyskinesia: Out of the shadows
The approvals of the first two medications, valbenazine and deutetrabenazine, to treat tardive dyskinesia have ushered in a new era in neuropsychiatric care. Tardive syndromes are defined as delayed onset, persistent movement disorders or sensory phenomena that occur in association with exposure to dopamine receptor blocking agents (DRBAs). Their underlying pathophysiology remains to be fully elucidated, but clinicians can conceptualize tardive syndromes as persistent dopamine super sensitivity states.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Robert A. Hauser, Daniel Truong Tags: Review Article Source Type: research